Literature DB >> 20186151

Sporadic solitary aldosterone- and cortisol-co-secreting adenomas: endocrine, histological and genetic findings in a subtype of primary aldosteronism.

Holger S Willenberg1, Martin Späth, Christiane Maser-Gluth, Rainer Engers, Martin Anlauf, Gabriele Dekomien, Matthias Schott, Sven Schinner, Kenko Cupisti, Werner A Scherbaum.   

Abstract

Adrenal adenomas producing both aldosterone and cortisol (A/CPAs) have been described in only a few cases. Correct subtype classification is necessary for making therapeutic decisions in primary aldosteronism (PA). Therefore, we studied in detail the clinical, hormonal and histological features of this entity in two patients with A/CPAs. We describe two patients with A/CPA and present their endocrine evaluations at baseline, after suppression with fludrocortisone and dexamethasone, after therapy with spironolactone and after unilateral adrenalectomy. Moreover, the expression of corticotropin (MC2R) and angiotensin II type 1 (AT1R) receptors and 17alpha-hydroxylase in the tumors of these two patients was analyzed by immunohistochemistry. Aldosterone, 18-hydroxycorticosterone (18-OH-B) and 18-hydroxycortisol (18-OH-F) were not suppressible with fludrocortisone in either patient and were partly suppressible with dexamethasone in one of the patients. Adrenal insufficiency developed in both patients after operation and lasted for more than 6 months. Aldosterone and hybrid corticosteroids returned to normal 8 weeks after adrenalectomy. In both cases, immunostaining showed weak expression of AT1R and MC2R but strong expression of 17alpha-hydroxylase. The most common germline mutations in the aldosterone synthase gene and the aldosterone synthase/11beta-hydroxylase hybrid gene were absent. These two cases document the fact that sporadic A/CPA is a subtype of PA. The presence of an A/CPA should be considered if a patient has both PA and hypercortisolism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20186151     DOI: 10.1038/hr.2010.18

Source DB:  PubMed          Journal:  Hypertens Res        ISSN: 0916-9636            Impact factor:   3.872


  7 in total

1.  A patient with concurrent primary aldosteronism and Page kidney.

Authors:  Chin-Chi Kuo; Huan-Lun Hsu; Chao-Yuan Huang; Kao-Lang Liu; Vin-Cent Wu; Ching-Wei Tsai; Wei-Jie Wang
Journal:  Endocrine       Date:  2010-06-24       Impact factor: 3.633

2.  Primary Aldosteronism and ARMC5 Variants.

Authors:  Mihail Zilbermint; Paraskevi Xekouki; Fabio R Faucz; Annabel Berthon; Alexandra Gkourogianni; Marie Helene Schernthaner-Reiter; Maria Batsis; Ninet Sinaii; Martha M Quezado; Maria Merino; Aaron Hodes; Smita B Abraham; Rossella Libé; Guillaume Assié; Stéphanie Espiard; Ludivine Drougat; Bruno Ragazzon; Adam Davis; Samson Y Gebreab; Ryan Neff; Electron Kebebew; Jérôme Bertherat; Maya B Lodish; Constantine A Stratakis
Journal:  J Clin Endocrinol Metab       Date:  2015-03-30       Impact factor: 5.958

3.  A Novel Phenotype of Familial Hyperaldosteronism Type III: Concurrence of Aldosteronism and Cushing's Syndrome.

Authors:  Anli Tong; Guanghua Liu; Fen Wang; Jun Jiang; Zhaoli Yan; Dianxi Zhang; Yinsheng Zhang; Jun Cai
Journal:  J Clin Endocrinol Metab       Date:  2016-07-12       Impact factor: 5.958

Review 4.  New Advances in the Diagnostic Workup of Primary Aldosteronism.

Authors:  Martin J Wolley; Michael Stowasser
Journal:  J Endocr Soc       Date:  2017-01-27

5.  Aldosterone- and cortisol-cosecreting adrenal adenoma, ovarian hyperthecosis and breast cancer.

Authors:  John J Orrego; Joseph A Chorny
Journal:  Endocrinol Diabetes Metab Case Rep       Date:  2020-09-23

6.  Aldosterone is Aberrantly Regulated by Various Stimuli in a High Proportion of Patients with Primary Aldosteronism.

Authors:  Matthieu St-Jean; Isabelle Bourdeau; Marc Martin; André Lacroix
Journal:  J Clin Endocrinol Metab       Date:  2021-01-01       Impact factor: 5.958

Review 7.  Intracellular Molecular Differences in Aldosterone- Compared to Cortisol-Secreting Adrenal Cortical Adenomas.

Authors:  Eric Seidel; Ute I Scholl
Journal:  Front Endocrinol (Lausanne)       Date:  2016-06-27       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.